Terrosa is a medication primarily used in the treatment of osteoporosis in postmenopausal women, aiming to reduce the risk of vertebral and hip fractures. It is a biosimilar to the original biologic medicine, teriparatide, which is a recombinant form of parathyroid hormone (PTH). Terrosa works by stimulating bone formation, increasing bone mineral density and bone strength. It is administered through subcutaneous injection, usually once a day, offering an alternative for patients who may not respond to or tolerate other osteoporosis treatments. As with any medication, it is important for patients to discuss the potential benefits and risks of using Terrosa with their healthcare provider.